Edition:
United States

Imprimis Pharmaceuticals Inc (IMMY.OQ)

IMMY.OQ on NASDAQ Stock Exchange Capital Market

2.48USD
22 Mar 2017
Change (% chg)

-- (--)
Prev Close
$2.48
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
22,584
52-wk High
$4.44
52-wk Low
$1.66

Latest Key Developments (Source: Significant Developments)

Imprimis Pharmaceuticals implemented an expense reduction program
Monday, 26 Sep 2016 08:30am EDT 

Imprimis Pharmaceuticals Inc : Co implemented an expense reduction program . Has ceased operations at its Texas facility and implemented an 8% reduction in total headcount . Exploring alternatives for use of Texas facility, estimates will incur total restructuring costs of about $0.6 million under plan .Actions are expected to streamline Imprimis' operations and reduce expected cash based expenses by nearly $3 million annually.  Full Article

Imprimis Pharmaceuticals Q2 revenue $4.9 million
Monday, 15 Aug 2016 04:03pm EDT 

Imprimis Pharmaceuticals Inc : Imprimis pharmaceuticals announces second quarter 2016 financial results . Q2 revenue rose 150 percent to $4.9 million .Qtrly net loss per common share $0.35.  Full Article

Imprimis Pharmaceuticals $2 mln sale agreement with Essex Capital
Thursday, 11 Aug 2016 08:30am EDT 

Imprimis Pharmaceuticals Inc : Agreement covers sale and leaseback of Imprimis' drug manufacturing equipment and has an initial term of up to three years . Agreement covers an additional one-year lease extension, subject to Imprimis achieving certain financial milestones .Imprimis Pharmaceuticals announces $2 million equipment sale leaseback agreement with Essex Capital Corporation.  Full Article

Imprimis Pharmaceuticals Q1 loss per share $0.43
Thursday, 12 May 2016 04:10pm EDT 

Imprimis Pharmaceuticals Inc : Q1 loss per share $0.43 . Imprimis pharmaceuticals announces first quarter 2016 financial results and provides business update .Q1 revenue $4.4 million versus $1.6 million.  Full Article

Imprimis Pharmaceuticals, Inc announces pricing of public offering of common stock
Friday, 11 Mar 2016 08:45am EST 

Imprimis Pharmaceuticals, Inc:Pricing of an underwritten public offering of 2.9 million shares of its common stock at a price to the public of $3.60 per share, before underwriting discounts.Offering is expected to close on or about March 16, 2016, subject to satisfaction of customary closing conditions.  Full Article

Imprimis Pharmaceuticals Inc reaffirms FY 2015 revenue guidance
Thursday, 12 Nov 2015 04:03pm EST 

Imprimis Pharmaceuticals Inc:Projects total revenue for FY 2015 to be approximately $9 - $11 million.  Full Article

Imprimis Pharmaceuticals Inc closes the acquisition of assets provider of compounded of Sinus Medications in U.S.
Tuesday, 20 Oct 2015 08:00am EDT 

Imprimis Pharmaceuticals Inc:Says through its unit , it has acquired substantially all of assets and tradenames of Thousand Oaks Holding Company's units Topical Apothecary Group LLC , Aerosol Science Laboratories Inc, SinuTopic, Inc and Mycotoxins LLC.  Full Article

Imprimis Pharmaceuticals Inc lowers FY 2015 revenue guidance
Tuesday, 20 Oct 2015 07:30am EDT 

Imprimis Pharmaceuticals Inc:Projects total revenue for FY 2015 to be about $9 - $11 million.FY 2015 revenue of $12 million - Thomson Reuters I/B/E/S.  Full Article

Imprimis Pharmaceuticals enters into an asset purchase agreement - Form 8-K
Tuesday, 29 Sep 2015 08:01am EDT 

Imprimis Pharmaceuticals, Inc:Entered into asset purchase agreement with Thousand Oaks Holding Company and its wholly owned subsidiaries.Agreed to acquire all assets of sellers including, but not limited to, intellectual property rights, trademarks, copyrights, inventories, equipment, customer lists, databases, permits, or licenses, and to assume certain limited liabilities.Total cash purchase price of about $499,000, to be paid at closing.  Full Article

Imprimis Pharmaceuticals Inc gives FY 2015 revenue outlook above analysts' estimates
Wednesday, 12 Aug 2015 04:05pm EDT 

Imprimis Pharmaceuticals Inc:Expects FY 2015 total revenue of $12.0 to $13.5 million.FY 2015 revenue of $11.9 million - Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

BRIEF-Imprimis Pharmaceuticals enters into agreements with two accredited investors

* Agreements for a registered direct placement of 1.3 million shares of common stock at a price of $2.40 per share